MADISON, Wis. – University Research Park today announced that GenCell Biosystems Ltd., Limerick, Ireland, will locate its U.S. subsidiary in the park’s MGE Innovation Center. The decision comes after a lengthy selection process that included some of this country’s largest metropolitan areas and most successful bioscience hubs.
“We are extremely pleased to call the Madison area and University Research Park home,” said Robert Roeven, general manager of GenCell USA. “Establishing a headquarters in the United States enables us to be much closer to many of our customers. Locating in the Madison region gives us access to tremendous assets, many of which we couldn’t find anywhere else. GenCell is proud to be a part of a great community. We look forward to taking advantage of our proximity to UW and the great ideas and great people it produces.”
“We are pleased to welcome GenCell to the United States, southern Wisconsin and University Research Park,” said Greg Hyer, the park’s associate director. “GenCell joins a growing pool of major national and international companies that call the park home, including Roche, Kikkoman, Illumina and Mentor. We’re proud to host these and all of our outstanding companies and provide a strong link to the university, its talent and expertise.”
GenCell has developed a highly advanced, fully automated, flexible genetic analysis technology that uses minute amounts of oil as the media for its tests. This unique approach eliminates the need for traditional plastic test consumables, and can be used for applications ranging from genotyping to library preparation for next generation sequencing.
“We are very pleased to welcome GenCell to the Madison region,” said Paul Jadin, president of the Madison Region Economic Partnership or MadREP. “GenCell has been growing quickly since its founding in Ireland just two years ago. We have the resources here in the Madison Region to ensure a successful start in the United States for GenCell and its continued, long-term growth. By its choice of the Madison Region, we know GenCell agrees.”